Table 1. Comparison of demographic and clinical characteristics between IV and IV + PO groups.
| All (n = 60) | IV group (n = 32) | IV+PO group (n = 28) | P-value | |||
|---|---|---|---|---|---|---|
| Age (median, IQR) | 60.0(50.0, 71.0) | 62.5(58.0, 71.0) | 57.5(44.3, 70.0) | 0.060 | a | |
| Male gender | 35(58.33%) | 20(62.50%) | 15(53.57%) | 0.601 | b | |
| Place of acquisition | 0.039 | b | ||||
| Community-acquired | 1(1.67%) | 0(0.00%) | 1(3.57%) | |||
| Hospital onset | 39(65.00%) | 25(78.13%) | 14(50.00%) | |||
| Healthcare-associated | 20(33.33%) | 7(21.88%) | 13(46.43%) | |||
| Hematologic malignancy | 4(6.67%) | 2(6.25%) | 2(7.14%) | >0.999 | b | |
| Solid tumor | 56(93.33%) | 30(93.75%) | 26(92.86%) | >0.999 | b | |
| Types of neoplasm | 0.543 | b | ||||
| Lip, oral cavity, and pharynx | 7(11.67%) | 6(18.75%) | 1(3.57%) | |||
| Digestive organs | 30(50.00%) | 16(50.00%) | 14(50.00%) | |||
| Respiratory and intrathoracic organs | 5(8.33%) | 3(9.38%) | 2(7.14%) | |||
| Bone and articular cartilage | 2(3.33%) | 0(0.00%) | 2(7.14%) | |||
| Mesothelial and soft tissue | 3(5.00%) | 1(3.13%) | 2(7.14%) | |||
| Female genital organs | 2(3.33%) | 1(3.13%) | 1(3.57%) | |||
| Urinary tract | 3(5.00%) | 2(6.25%) | 1(3.57%) | |||
| Ill-defined, other secondary, and unspecified sites | 4(6.67%) | 2(6.25%) | 2(7.14%) | |||
| Others | 4(6.67%) | 1(3.13%) | 3(10.71%) | |||
| Organ transplantation | 0(0.00%) | 0(0.00%) | 0(0.00%) | |||
| Immunosuppressant | 0(0.00%) | 0(0.00%) | 0(0.00%) | |||
| Glucocorticoid therapy | 7(11.67%) | 2(6.25%) | 5(17.86%) | 0.235 | b | |
| Total parenteral nutrition | 27(45.00%) | 16(50.00%) | 11(39.29%) | 0.446 | b | |
| Antineoplastic chemotherapy | 45(75.00%) | 24(75.00%) | 21(75.00%) | >0.999 | b | |
| Diabetes mellitus | 14(23.33%) | 8(25.00%) | 6(21.43%) | 0.770 | b | |
| Chronic kidney disease | 3(5.00%) | 3(9.38%) | 0(0.00%) | 0.241 | b | |
| Neutropenia | 1(1.85%) | 1(3.33%) | 0(0.00%) | >0.999 | b | |
| Hemodialysis | 2(3.33%) | 2(6.25%) | 0(0.00%) | 0.494 | b | |
| Valve disease | 4(6.67%) | 3(9.38%) | 1(3.57%) | 0.616 | b | |
| Type of CVCs | 0.064 | b | ||||
| Short-term central venous catheter | 23(38.33%) | 16(50.00%) | 7(25.00%) | |||
| PICC | 1(1.67%) | 0(0.00%) | 1(3.57%) | |||
| Implanted port | 36(60.00%) | 16(50.00%) | 20(71.43%) | |||
| Presence of a non-removable foreign body | 0.402 | b | ||||
| IV filter | 1(1.67%) | 0(0.00%) | 1(3.57%) | |||
| None | 56(93.33%) | 31(96.88%) | 25(89.29%) | |||
| Others | 3(5.00%) | 1(3.13%) | 2(7.14%) | |||
| Pitt Bacteremia Score | 0.841 | a | ||||
| 0 | 31(52.54%) | 16(51.61%) | 15(53.57%) | |||
| 1 | 19(32.20%) | 10(32.26%) | 9(32.14%) | |||
| 2 | 1(1.69%) | 1(3.23%) | 0(0.00%)) | |||
| 3 | 2(3.39%) | 1(3.23%) | 1(3.57%) | |||
| 4 | 4(6.78%) | 1(3.23%) | 3(10.71%) | |||
| 8 | 2(3.39%) | 2(6.45%) | 0(0.00%) | |||
| Secondary foci | ||||||
| Postoperative wound | 1(1.67%) | 1(3.13%) | 0(0.00%) | >0.999 | b | |
| Pneumonia | 1(1.67%) | 0(0.00%) | 1(3.57%) | 0.467 | b | |
| Skin soft tissue | 1(1.67%) | 1(3.13%) | 0(0.00%) | >0.999 | b | |
| Endocarditis | 1(1.67%) | 1(3.13%) | 0(0.00%) | >0.999 | b | |
| Thromboembolism | 6(10.00%) | 0(0.00%) | 6(21.43%) | 0.008 | b | |
| Liver abscess | 1(1.67%) | 0(0.00%) | 1(3.57%) | 0.467 | b | |
| Persistent bacteremia | 6(20.00%) | 1(7.69%) | 5(29.41%) | 0.196 | b | |
| Removed CVCs | 55(91.67%) | 27(84.38%) | 28(100.00%) | 0.055 | b | |
| Drainage except for removing CVCs | 5(8.33%) | 2(6.25%) | 3(10.71%) | 0.657 | b | |
| CVCs reinsertion during antibiotic treatment | 24(40.00%) | 15(46.88%) | 9(32.14%) | 0.297 | b | |
| Complication after treatment | ||||||
| Thromboembolism | 5(8.33%) | 1(3.13%) | 4(14.29%) | 0.175 | b | |
| Osteomyelitis | 1(1.67%) | 0(0.00%) | 1(3.57%) | 0.467 | b | |
| Skin soft tissue | 1(1.67%) | 0(0.00%) | 1(3.57%) | 0.467 | b | |
| None | 55(91.67%) | 31(96.88%) | 24(85.71%) | 0.175 | b | |
| ID consultation | 47(78.33%) | 21(65.63%) | 26(92.86%) | 0.013 | b | |
| Received echocardiogram | 38(63.33%) | 14(43.75%) | 24(85.71%) | 0.001 | b | |
| IV antibiotics | ||||||
| CEZ | 56(93.33%) | 29(90.63%) | 27(96.43%) | 0.616 | b | |
| CMZ | 3(5.00%) | 2(6.25%) | 1(3.57%) | >0.999 | b | |
| CTRX | 4(6.67%) | 3(9.38%) | 1(3.57%) | 0.616 | b | |
| CFPM | 24(40.00%) | 9(28.13%) | 15(53.57%) | 0.065 | b | |
| SBT/CPZ | 5(8.33%) | 4(12.50%) | 1(3.57%) | 0.359 | b | |
| SBT/ABPC | 6(10.00%) | 3(9.38%) | 3(10.71%) | >0.999 | b | |
| TAZ/PIPC | 12(20.00%) | 5(15.63%) | 7(25.00%) | 0.520 | b | |
| IPM/CS | 3(5.00%) | 1(3.13%) | 2(7.14%) | 0.594 | b | |
| MEPM | 3(5.00%) | 2(6.25%) | 1(3.57%) | >0.999 | b | |
| VCM | 50(83.33%) | 23(71.88%) | 27(96.43%) | 0.014 | b | |
| CLDM | 6(10.00%) | 2(6.25%) | 4(14.29%) | 0.404 | b | |
| others | 2(3.34%) | 2(6.25%) | 0(0.00%) | |||
| PO antibiotics | ||||||
| CEX | 19(31.67%) | 19(67.86%) | ||||
| CVA/AMPC | 4(6.67%) | 4(14.29%) | ||||
| LVFX | 4(6.67%) | 4(14.29%) | ||||
| ST | 2(3.33%) | 2(7.14%) | ||||
| CLDM | 6(10.00%) | 6(21.43%) | ||||
| others | 2(3.33%) | 2(7.14%) | ||||
| Duration of antibiotics days (median, range) | 26.0(15,0, 34.0) | 16.5(13.0,30.5) | 32.5(26.0,52.3) | <0.001 | b | |
| Duration of IV antibiotics (median, range) | 17.0(13.0,24.75) | 16.5(13.0,30.5) | 17.5(13.0,24.0) | 0.935 | b | |
| Recurrence | 1(1.67%) | 1(3.13%) | 0(0.00%) | >0.999 | b | |
| Infection-related death | 0(0.00%) | 0(0.00%) | 0(0.00%) | |||
| Death within 90 days | 20(33.33%) | 17(53.13%) | 3(10.71%) | 0.001 | b | |
| Death within 30 days | 7(11.67%) | 7(21.88%) | 0(0.00%) | 0.012 | b | |
data: n, %; median [interquartile range (IQR): 25%, 75%].
a, Mann-Whitney U test
b, Fisher's Exact Test.
Abbreviations; IV, intravenous; PO, oral; IQR, interquartile range; CVCs, central venous catheters; PICC, peripherally inserted central catheter; ID, infectious disease; CEZ, Cefazolin; CMZ, Cefmetazole; IPM/CS, Imipenem/Cilastatin; MEPM, Meropenem; VCM, vancomycin; CLDM, Clindamycin; CEX, Cefalexin; CVA/AMPC, Amoxicillin/Clavulanate; LVFX, Levofloxacin; ST, Sulfamethoxazole/Trimethoprim.